Safety Profile
Known Safety Concerns
- Osmotic diarrhoea above 50 g/day
- Gas and bloating with high consumption during gut microbiome adaptation
- May cause loose stools at high doses
- FDA GRAS -- safe at supplement amounts
Contraindications
- Osmotic diarrhoea above 50 g/day
- Gas and bloating with high consumption during gut microbiome adaptation
Interactions
Information not yet available for this ingredient profile.
Evidence and Scientific Findings
Ingredient Overview
Polydextrose is a partially digestible glucose polymer used as a low-calorie filler and prebiotic fibre. Provides approximately 1 kcal/g. FDA approved as Generally Recognised As Safe (GRAS). At high doses (above 50 g/day) causes osmotic diarrhoea. Well tolerated at typical supplement levels. Acts as a prebiotic.
Biological and Chemical Classification
- Scientific Name
- Polydextrose (randomly bonded glucose polymer)
Mechanism of Action
Information not yet available for this ingredient profile.
Clinical Evidence of Effectiveness
Information not yet available for this ingredient profile.
Pharmacokinetics
Information not yet available for this ingredient profile.
Recommended Dosage
Information not yet available for this ingredient profile.
SETI — Scientific Evidence Transparency Index
Executive Summary — Ingredient Assessment
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or RCT)
- Main clinical benefit observed: Excipient
- Evidence consistency: High consistency across studies (100%)
- Osmotic diarrhoea above 50 g/day
- Gas and bloating with high consumption during gut microbiome adaptation
- May cause loose stools at high doses
- FDA GRAS -- safe at supplement amounts
The available scientific evidence for Polydextrose indicates notable safety signals that warrant caution. Use should be considered carefully and monitored, particularly in sensitive populations or alongside other medications.
Total SETI Score
High risk| Evidence quality | 10/40 |
| Evidence consistency | 20/20 |
| Safety signals | 0/20 |
| Study recency | 10/10 |
| Evidence transparency | 10/10 |
Evidence Summary
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or systematic review)
- 0 studies identified benefits or no safety concern (GREEN)
- 10 studies reported limited or advisory safety evidence (YELLOW)
Evidence Policy
Only peer-reviewed scientific literature indexed in PubMed or comparable databases is included in this evaluation. Commercial websites, blogs, and marketing materials are excluded. All references include direct traceable links to source documents.
Last updated: 25 მარ 2026, 12:57
Evidence Distribution
-
Observational / other LOW evidence YELLOWImmunological and periodontal benefits of prebiotic polydextrose in rats with induced periodontitis. ↗Nassar RSF et al.. Immunological and periodontal benefits of prebiotic polydextrose in rats with induced periodontitis.. J Periodontol. 2026. PMID:41711356.PMID 41711356 ↗Journal J PeriodontolYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41711356/
-
Observational / other LOW evidence YELLOWPartially hydrolyzed cow's milk protein formula with an added prebiotic is well-tolerated, safe, and supports age-appropriate growth in healthy term infants through… ↗Fabrizio V et al.. Partially hydrolyzed cow's milk protein formula with an added prebiotic is well-tolerated, safe, and supports age-appropriate growth in healthy term infants through one year of age: DBRCT.. BMC Pediatr. 2026. PMID:41527066.PMID 41527066 ↗Journal BMC PediatrYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41527066/
-
Observational / other LOW evidence YELLOWPrebiotics as adjunctive treatment ameliorates DSS-induced colitis and gut microbiota. ↗Kong Y et al.. Prebiotics as adjunctive treatment ameliorates DSS-induced colitis and gut microbiota.. Microbiol Spectr. 2026. PMID:41363846.PMID 41363846 ↗Journal Microbiol SpectrYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41363846/
-
Observational / other LOW evidence YELLOWThe Role of Dietary Fiber in Health Promotion and Disease Prevention: A Practical Guide for Clinicians. ↗Daley SF et al.. The Role of Dietary Fiber in Health Promotion and Disease Prevention: A Practical Guide for Clinicians.. 2026. PMID:32644459.PMID 32644459 ↗Year 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/32644459/
-
Observational / other LOW evidence YELLOWAnti-freezing, self-healing and human sensors nanocomposite hydrogels based on functionalized cellulose nanocrystals and polydextrose. ↗Feng S et al.. Anti-freezing, self-healing and human sensors nanocomposite hydrogels based on functionalized cellulose nanocrystals and polydextrose.. Carbohydr Polym. 2026. PMID:41274732.PMID 41274732 ↗Journal Carbohydr PolymYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41274732/
-
Observational / other LOW evidence YELLOWNew infant formulas for healthy term infants: A randomized, controlled, double-blind, multicenter, non-inferiority design safety study. ↗Fleming SA et al.. New infant formulas for healthy term infants: A randomized, controlled, double-blind, multicenter, non-inferiority design safety study.. PLoS One. 2025. PMID:41406156.PMID 41406156 ↗Journal PLoS OneYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41406156/
-
Observational / other LOW evidence YELLOWA Randomized Controlled Trial of a Partially Hydrolyzed Formula on Comfort Measures in Fussy Infants. ↗Fabrizio V et al.. A Randomized Controlled Trial of a Partially Hydrolyzed Formula on Comfort Measures in Fussy Infants.. Curr Dev Nutr. 2025. PMID:41323693.PMID 41323693 ↗Journal Curr Dev NutrYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41323693/
-
Observational / other LOW evidence YELLOWFunctional and Metabolomic Analyses of Chamomile Jelly Derived from Gelatin Capsule Waste with Inulin and Polydextrose as Prebiotic Sugar Substitutes. ↗Sanprasert S et al.. Functional and Metabolomic Analyses of Chamomile Jelly Derived from Gelatin Capsule Waste with Inulin and Polydextrose as Prebiotic Sugar Substitutes.. Antioxidants (Basel). 2025. PMID:41300536.PMID 41300536 ↗Journal Antioxidants (Basel)Year 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41300536/
-
Observational / other LOW evidence YELLOWMechanism of emulsion stabilized by an ultrasonically prepared protein-polyphenol-polysaccharide complex: structure, functional properties and interfacial behavior. ↗Huang Y et al.. Mechanism of emulsion stabilized by an ultrasonically prepared protein-polyphenol-polysaccharide complex: structure, functional properties and interfacial behavior.. Ultrason Sonochem. 2025. PMID:41130178.PMID 41130178 ↗Journal Ultrason SonochemYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41130178/
-
Observational / other LOW evidence YELLOWPolydextrose reduces the infection of Klebsiella pneumoniae in mice by downregulating the expression of TamA. ↗Su L et al.. Polydextrose reduces the infection of Klebsiella pneumoniae in mice by downregulating the expression of TamA.. Microbiol Spectr. 2025. PMID:41031838.PMID 41031838 ↗Journal Microbiol SpectrYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41031838/
Score Transparency
0 of 10 approved references (score saturates at 10). More peer-reviewed studies = stronger evidence base.
Method: Q = number of approved references ÷ 10 (capped at 1.0)
Limited — mostly case reports or animal studies
Method: L = mean study-level weight across approved references. Level 1 (meta-analysis / systematic review) = 1.0; Level 2 (RCT) = 0.8; Level 3 (cohort/case-control) = 0.6; Level 4 (case report) = 0.4; Level 5 (animal / in-vitro) = 0.2.
Mixed or neutral — roughly equal benefit and risk signals
Method: D = (sum of risk-scored references − sum of benefit-scored references) ÷ total evidence score, then scaled from [−1, 1] to [0, 1]. 0.0 = pure benefit; 0.5 = neutral; 1.0 = pure risk.
One or more monitoring-level safety signals active
Method: S = 0.5 (neutral baseline) + sum of active signal severity deltas ÷ 10. Severity deltas: Critical = +2.0, High = +1.5, Moderate = +1.0, Low = +0.5. Capped at 1.0.
Final GIRI Score for Polydextrose. Risk level thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
Full methodology & data sources
The GIRI Score is computed entirely from structured data — no editorial scoring or subjective weighting is applied at any step.
- References: Only approved references are counted. Each reference is assigned an evidence level (L1–L5) and a direction (risk / neutral / benefit) by the reference manager or AI classifier.
- Safety Signals: Sourced from regulatory agencies (FDA, EMA, Health Canada, TGA, and others) and pharmacovigilance databases. Only active signals count toward the score.
- Formula version: GIRI Score v3.7.0 — Q × L × D × S × 10.
- Limitations: The score reflects published evidence and recorded signals as of the last update date. It is not a clinical risk assessment and should not replace advice from a qualified healthcare professional.
Risk Level Classification
Based on available regulatory signals and scientific evidence, this ingredient presents a low safety concern under normal conditions of use.
0–3.0
3.0–5.5
5.5–7.5
7.5–10
The score pin shows exactly where this ingredient falls on the fixed risk scale.
What drove the Low classification for Polydextrose
A score of 2.0 places this ingredient in the Low band. Thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
0 approved references.
Limited — mostly case reports or animal studies (Level 4–5).
Neutral or mixed — benefit and risk signals roughly balanced.
No active signals — S component is at neutral baseline (0.5), contributing no extra risk weight.
No major regulatory restrictions or advisories recorded across monitored jurisdictions (FDA, EMA, Health Canada, TGA, and others).
How are the Low / Moderate / High / Critical thresholds defined?
The four risk levels are fixed score bands. A score is assigned to exactly one level based on where it falls:
| Level | Score | Meaning |
|---|---|---|
| LOW | 0.0 – 2.9 | Sparse or predominantly beneficial evidence. No active safety alerts. |
| MODERATE | 3.0 – 5.4 | Mixed signals — some risk alongside benefit. Caution at high doses or in sensitive groups. |
| HIGH | 5.5 – 7.4 | Multiple studies or regulatory alerts documenting adverse effects. Professional oversight recommended. |
| CRITICAL | 7.5 – 10 | Regulatory restrictions in one or more major jurisdictions. Serious documented harm. Avoid without specialist supervision. |
Thresholds are fixed constants (GIRI_Score_Utils::LEVEL_THRESHOLDS). They do not change per ingredient and are never subject to editorial adjustment.